Meeting
2020 Genitourinary Cancers Symposium
Impact of 18F-fluciclovine PET on salvage radiotherapy plans for men with post-radical prostatectomy recurrence of prostate cancer.
Authors
Heather Ann Payne
University College London Hospitals NHS Foundation Trust, London, United Kingdom
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Imaging
Clinical Trial Registration Number
NCT02578940
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 19)
Abstract #
19
Poster Bd #
A7
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans.
First Author: Julio Chong
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of 18F-flotufolastat PET on management of patients with recurrent prostate cancer: Data from the SPOTLIGHT study.
First Author: Przemyslaw Twardowski
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2, multicenter, randomized study of salvage radiation therapy +/- metformin for recurrent prostate cancer after radical prostatectomy (SAKK 08/15 – GETUG-AFU 34 PROMET trial).
First Author: Alan Dal Pra